Unknown

Dataset Information

0

A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer.


ABSTRACT: BACKGROUND:The prognosis of metastatic colorectal cancer (mCRC) is poor. We assessed the feasibility, safety, and efficacy of the anti-programmed cell death 1 fusion protein AMP-224 in combination with low-dose cyclophosphamide and stereotactic body radiation (SBRT) treatment in patients with mCRC refractory to standard chemotherapy. PATIENTS AND METHODS:Fifteen patients were enrolled. Six received SBRT 8 Gy on day 0 (dose level 1), whereas 9 received 8 Gy on days -2 to day 0. All received cyclophosphamide 200 mg/m2 intravenously (I.V.) on day 0. On day 1, both groups received AMP-224 10 mg/kg I.V., repeated every 2 weeks for a total of 6 doses. Primary end points were feasibility and safety. RESULTS:Ten (67%) patients completed 6 doses of AMP-224; 5 patients (33%) discontinued treatment because of disease progression. No dose-limiting toxicity was observed; 9 patients (60%) experienced treatment-related adverse events, all Grade 1 or 2. No objective response was noted; 3 patients (20%) had stable disease. Median progression-free survival and overall survival were 2.8 months (95% confidence interval [CI], 1.2-2.8 months) and 6.0 months (95% CI, 2.8-9.6 months), respectively. M2 macrophage polarization was present in the pretreatment tumor biopsy samples, but not post-treatment samples. CONCLUSION:AMP-224 in combination with SBRT and low-dose cyclophosphamide was well tolerated, however, no significant clinical benefit was observed in patients with mCRC.

SUBMITTER: Floudas CS 

PROVIDER: S-EPMC6884678 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer.

Floudas Charalampos S CS   Brar Gagandeep G   Mabry-Hrones Donna D   Duffy Austin G AG   Wood Bradford B   Levy Elliot E   Krishnasamy Venkatesh V   Fioravanti Suzanne S   Bonilla Cecilia M CM   Walker Melissa M   Morelli Maria Pia MP   Kleiner David E DE   Steinberg Seth M SM   Figg William D WD   Greten Tim F TF   Xie Changqing C  

Clinical colorectal cancer 20190702 4


<h4>Background</h4>The prognosis of metastatic colorectal cancer (mCRC) is poor. We assessed the feasibility, safety, and efficacy of the anti-programmed cell death 1 fusion protein AMP-224 in combination with low-dose cyclophosphamide and stereotactic body radiation (SBRT) treatment in patients with mCRC refractory to standard chemotherapy.<h4>Patients and methods</h4>Fifteen patients were enrolled. Six received SBRT 8 Gy on day 0 (dose level 1), whereas 9 received 8 Gy on days -2 to day 0. All  ...[more]

Similar Datasets

| 2178897 | ecrin-mdr-crc
| S-EPMC6891218 | biostudies-literature
| S-EPMC6906721 | biostudies-literature
| S-EPMC7295942 | biostudies-literature
| S-EPMC2858487 | biostudies-literature
| S-EPMC4984796 | biostudies-other
| S-EPMC8172819 | biostudies-literature
| S-EPMC7647381 | biostudies-literature
| S-EPMC7406342 | biostudies-literature
| S-EPMC5201122 | biostudies-literature